Anticorps Polyclonal de lapin anti-C11orf82

C11orf82 Polyclonal Antibody for WB, Indirect ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

WB, Indirect ELISA

Conjugaison

Non conjugué

N° de cat : 27754-1-PBS

Synonymes

noxin, Nitric oxide-inducible gene protein, DNA damage-induced apoptosis suppressor protein, DNA Damage Induced Apoptosis Suppressor, DDIAS

---

Galerie de données de validation

• 

  WB analysis using 27754-1-AP (same clone as 27754-1-PBS)

  Various lysates were subjected to SDS PAGE followed by western blot with 27754-1-AP (C11orf82 antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 27754-1-PBS in a different storage buffer formulation.

---

Informations sur le produit

27754-1-PBS cible C11orf82 dans les applications de WB, Indirect ELISA et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: C11orf82 Protéine recombinante Ag26829
• Nom complet: chromosome 11 open reading frame 82
• Poids moléculaire observé: 120 kDa
• Numéro d’acquisition GenBank: BC039268
• Symbole du gène: C11orf82
• Identification du gène (NCBI): 220042
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS only
• Conditions de stockage: Store at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

DNA damage-induced apoptosis suppressor (DDIAS) is an oncogenic protein that is highly expressed in several cancers, including colorectal, lung, breast, and hepatocellular carcinoma (HCC), and stimulates cancer cell proliferation and cell cycle progression.DDIAS protects cancer cells from DNA damage reagents and tumor necrosis factor-associated apoptosis-inducing ligands (TRAILs) and positively regulates cancer cell invasion by stabilizing the β- catenin positively regulates cancer cell invasion. Therefore, DDIAS is considered as a potential therapeutic target for malignant lung cancer.

{{ptg:RelatedPrimaryAntibodies}}